OTP E 1402, TO THE STATE OF THE TRANSMENT OF THE TRANSMEN

CASE ON/4-32548A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274152 4S

DANUARY 23, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

JOSEPH ALEXANDER LASKY

INTERNATIONAL APPLICATION NO: PCT/#B03/02794

FILED: 17 JUNE 2003

U.S. APPLICATION NO: 10/518,988 V

35 USC §371 DATE: 7 NOVEMBER 2006

FOR: 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYLJ-BENZAMIDE FOF TREATING PULMONARY FIBROSIS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicant

Reg. No. 48,152

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7852

Date: 1/23/07

Sheet 1 of 2

FORM PTO-1449 (REV. 7-85)

several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. ON/4-32548A APPLICATION NO. 10/518.988 APPLICANT Joseph Alexander LASKY FILING DATE NOVEMBER 7, 2006

Group

JAN 2 3 2007

U.C. DATENT DOGUMENTS

EXAMINER							
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	ΑE						
	AF						
	AG						
	АН						
	ΑI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
AM	* WO 99/03854	01/28/99	WIPO				
AN							
AO							
AP							
AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	American Thoracic Society, "Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment, Am J Respir Crit Care Med, Vol. 161, pp. 646-664 (2000).
AS	* Beers, "Idiopathic Bronchiolitis Obitterans with Organizing Pneumonia", The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories, Whitehouse Station, NJ, pp. 638-639 (1999).
AT	* Boecklin et al., "Anti-fibrogenic Effect of the Tyrosine Kinase Inhibitor STI-571 on Bone Marrow Fibrosis in Chronic Myeloid Leukemia", <i>Blood</i> , Vol. 96, No. 11, Pt. 1, p. 734a (2000).

EXAMINER **DATE CONSIDERED** /Craig Ricci/ 05/27/2008 *EXAMINER:

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 2 of 2

FORM PTO-1449
(REV. 7-85)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION

tse several sheets if necessary)

ATTY. DOCKET NO. ON/4-32548A APPLICATION NO. 10/518,988 APPLICANT Joseph Alexander LASKY FILING DATE NOVEMBER 7, 2006

Group

THER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

TRADES!		December 1 Washington Comment					
	DA	Bonner et al., "Induction of PDGF Re Fibrogenesis In Vivo", Am J Physiol,	ceptor-alpha in Rat Myofibroblasts During Pulmonary Vol. 274, Suppl. 1, Pt. 1, pp. L72-L80 (1998).				
	DB	Driscoll et al., "Stimulation of Rat Alv. Model of Lung Injury and Fibrosis", 7 (Abstract).	eolar Macrophage Fibronectin Release in a Cadmium Chloride ioxicol Appl Pharmacol, Vol. 116, No. 1, pp. 30-37 (1992)				
	DC	Fauci et al., Harrison's Principles of Internal Medicine, Vol. 2, 14th Edition, McGraw-Hill (1997).					
	DD	Gross and Hunninghake, "Idiopathic Pulmonary Fibrosis", New Engl J Med. Vol. 345, No. 7, pp. 517-525 (2001).					
	DE	Harrison's Online, "Individual Forms of ILD", Chapter 259: Interstitial Lung Diseases, p. 14.					
	DF	John et al., "Increased Production of Matrix Metalloproteinase-2 in Alveolar Macrophages and Regulation by Interleukin-10 in Patients with Acute Pulmonary Sarcoidosis", Exp Lung Res, Vol. 28, No. 1, pp. 55-68 (2002) (abstract)					
	DG	Katzenstein and Meyers, "Idiopathic Pulmonary Fibrosis. Clinical Relevance of Pathologic Classification", Am J Respir Crit Care Med, Vol. 157, No. 4, pp. 1301-1315 (1998).					
	DH	King, Jr., "Interstitial Lung Disease, Harrison's Online, Chapter 259, p. 1.					
	DΙ	Lasky and Brody, "Interstitial Fibrosis and Growth Factors", Environ Health Perspect, Vol. 108, No. 8, Suppl. 4, pp. 751-762 (2000).					
	DJ	Lindroos, Wang, Rice and Bonner, "Regulation of PDGRF-α in Rat Pulmonary Myofibroblasts by Staurosporine", Am J Physiol Lung Cell Mol Physiol, Vol. 280, No. 2, pp. L354-L352 (2001).					
	DK	Marshall, McAnulty and Laurent, "The Pathogenesis of Pulmonary Fibrosis: Is There a Fibrosis Gene?", Int J Biochem Cell Biol, Vol. 29, No. 1, pp. 107-120 (1997).					
	DL	Nagai, Nagao, Hoshino and Hamada, "Heterogeneity of Pulmonary Fibrosis: Interstitial Pneumonias and Sarcoidosis", <i>Curr Opin Pulm Med</i> , Vol. 7, No. 5, pp. 262-271 (2001).					
	DM	Paine, III and Ward, "Cell Adhesion Molecules and Pulmonary Fibrosis", Am J Med, Vol. 107, No. 3, pp. 268-279 (1999).					
	DN	Reynolds, "Interstitial Lung Diseases", Chapter 259, pp. 1460-1465.					
	DO	Pathol, Vol. 155, No. 1, pp. 213-221 (1999). Romanska et al., "Up-regulation of Inducible Nitric Oxide Synthase in Fibroblasts Parallels the					
	DP						
	DQ	Yousem, "Pulmonary Apical Caps: A Surgical Pathology", Am J Surg Pathology	Distinctive but Poorly Recognized Lesion in Pulmonary /, Vol. 25, No. 5, pp. 679-683 (2001) (Abstract)				
EXAMINER		/Craig Ricci/	DATE CONSIDERED 05/27/2008				

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.